CytoSorbents Narrows Full-Year Loss to $0.13/Share, Advances Key FDA Discussions
Summary
CytoSorbents reported its fourth quarter and full-year 2025 financial results, with a notable improvement in its full-year net loss, which narrowed to $0.13 per share from $0.38 per share in 2024. Full-year revenue increased by 4% to $37.1 million, although Q4 revenue growth was modest at 1% and declined on a constant currency basis. The company also provided an important update on ongoing interactive discussions with the FDA for a new De Novo application for its DrugSorb-ATR product. Furthermore, CytoSorbents implemented a strategic workforce and cost reduction program in Q4 2025, aimed at accelerating its path to cash flow breakeven in 2026. These strategic moves and the significant reduction in net loss are material for the company, despite a quarter-over-quarter decline in cash. Investors will closely monitor progress on the FDA application and the effectiveness of the cost reduction initiatives.
At the time of this announcement, CTSO was trading at $0.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42.2M. The 52-week trading range was $0.60 to $1.39. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.